VF
AKBA icon

Virtu Financial’s Akebia Therapeutics AKBA Stock Holding History

Virtu Financial’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34K Sell
24,511
-22,283
-48% -$30.6K ﹤0.01% 1336
2025
Q4 		$75K Buy
+46,794
New +$98K ﹤0.01% 1254
2024
Q4 		– Sell
-55,746
Closed -$74K – 1495
2024
Q3 		$74K Sell
55,746
-19,333
-26% -$25.8K ﹤0.01% 952
2024
Q2 		$77K Buy
+75,079
New +$92.8K 0.01% 854
2024
Q1 		– Sell
-59,479
Closed -$74K – 1365
2023
Q4 		$74K Buy
+59,479
New +$60.7K 0.01% 1093
2023
Q3 		– Sell
-50,633
Closed -$46K – 1244
2023
Q2 		$46K Sell
50,633
-47,221
-48% -$45.6K ﹤0.01% 1147
2023
Q1 		$55K Buy
+97,854
New +$74.8K 0.01% 1080
2022
Q2 		– Sell
-130,949
Closed -$94K – 1533
2022
Q1 		$94K Buy
+130,949
New +$280K 0.01% 985
2021
Q3 		– Sell
-46,270
Closed -$175K – 1451
2021
Q2 		$175K Sell
46,270
-117,262
-72% -$395K 0.02% 1047
2021
Q1 		$554K Buy
+163,532
New +$589K 0.04% 471
2020
Q4 		– Sell
-82,303
Closed -$207K – 1405
2020
Q3 		$207K Buy
+82,303
New +$722K 0.04% 582
2019
Q4 		$123K Buy
19,491
+543
+3% +$2.58K 0.01% 1043
2019
Q3 		$74K Buy
+18,948
New +$81.2K 0.01% 1138
2019
Q1 		– Sell
-28,181
Closed -$156K – 1380
2018
Q4 		$156K Buy
+28,181
New +$221K 0.01% 1029
2018
Q3 		– Sell
-10,097
Closed -$101K – 1498
2018
Q2 		$101K Sell
10,097
-13,255
-57% -$133K 0.01% 1645
2018
Q1 		$223K Buy
23,352
+10,965
+89% +$153K 0.01% 1272
2017
Q4 		$184K Buy
12,387
+2,015
+19% +$33.4K 0.01% 1717
2017
Q3 		$204K Buy
+10,372
New +$159K 0.01% 1831

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Virtu Financial's AKBA Position: Q1 2026 in Review

Virtu Financial reduced its Akebia Therapeutics (AKBA) stake by 48% in Q1 2026, selling an estimated $30.6K and leaving 24,511 shares worth $34K. The position accounts for ﹤0.01% of the portfolio, ranked #1336.

Virtu Financial first reported a position in AKBA in Q3 2017 and has held it in 18 quarters since. The position peaked at $554K in Q1 2021. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Virtu Financial held 24,511 shares of Akebia Therapeutics worth $34K as of Q1 2026.
  • Virtu Financial sold 22,283 Akebia Therapeutics shares in Q1 2026, an estimated $30.6K.
  • Akebia Therapeutics made up ﹤0.01% of Virtu Financial's portfolio in Q1 2026, its #1336 holding.
  • Virtu Financial first reported a position in Akebia Therapeutics in Q3 2017 and has held it in 18 quarters since.
  • Virtu Financial's Akebia Therapeutics position peaked at $554K in Q1 2021.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.